HealthEquity (NASDAQ:HQY) Issues FY25 Earnings Guidance

HealthEquity (NASDAQ:HQY) issued an update on its FY25 earnings guidance on Monday morning. The company provided EPS guidance of 3.08-3.16 for the period, compared to the consensus EPS estimate of $3.12. The company issued revenue guidance of $1.185-1.195 billion, compared to the consensus revenue estimate of $1.18 billion. HealthEquity also updated its FY 2025 guidance to 3.080-3.160 EPS.

HealthEquity Price Performance

Shares of HQY stock opened at $95.39 on Wednesday. HealthEquity has a 1-year low of $62.10 and a 1-year high of $105.82. The stock’s 50-day moving average is $93.11 and its 200 day moving average is $83.90. The company has a market cap of $8.33 billion, a P/E ratio of 79.49, a PEG ratio of 1.57 and a beta of 0.55. The company has a debt-to-equity ratio of 0.51, a current ratio of 4.10 and a quick ratio of 4.10.

Analyst Ratings Changes

A number of equities research analysts recently weighed in on HQY shares. Barrington Research raised their price objective on HealthEquity from $105.00 to $120.00 and gave the company an “outperform” rating in a research report on Monday, December 2nd. Mizuho began coverage on HealthEquity in a report on Wednesday, December 4th. They issued an “outperform” rating and a $126.00 price target for the company. JMP Securities raised their price target on HealthEquity from $105.00 to $107.00 and gave the stock a “market outperform” rating in a report on Tuesday. Bank of America raised their price target on HealthEquity from $100.00 to $120.00 and gave the stock a “buy” rating in a report on Wednesday, November 13th. Finally, Royal Bank of Canada raised their price target on HealthEquity from $100.00 to $105.00 and gave the stock an “outperform” rating in a report on Tuesday. One investment analyst has rated the stock with a hold rating and thirteen have issued a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and an average price target of $110.71.

Insider Transactions at HealthEquity

In related news, Director Frank Corvino sold 1,039 shares of HealthEquity stock in a transaction that occurred on Wednesday, November 6th. The stock was sold at an average price of $96.10, for a total transaction of $99,847.90. Following the completion of the transaction, the director now directly owns 3,784 shares in the company, valued at approximately $363,642.40. This trade represents a 21.54 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, Director Robert W. Selander sold 8,250 shares of HealthEquity stock in a transaction that occurred on Wednesday, October 9th. The shares were sold at an average price of $82.98, for a total value of $684,585.00. Following the transaction, the director now owns 54,719 shares of the company’s stock, valued at approximately $4,540,582.62. This represents a 13.10 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 10,536 shares of company stock worth $884,517 over the last three months. 2.20% of the stock is currently owned by insiders.

HealthEquity Company Profile

HealthEquity, Inc provides technology-enabled services platforms to consumers and employers in the United States. The company offers cloud-based platforms for individuals to make health saving and spending decisions, pay healthcare bills, receive personalized benefit information, earn wellness incentives, grow their savings, and make investment choices; and health savings accounts.